In the last trading session, 1.18 million Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) shares changed hands as the company’s beta touched 1.83. With the company’s per share price at $3.36 changed hands at -$0.3 or -8.20% during last session, the market valuation stood at $239.45M. ZNTL’s last price was a discount, traded about -437.8% off its 52-week high of $18.07. The share price had its 52-week low at $2.66, which suggests the last value was 20.83% up since then. When we look at Zentalis Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.96 million shares, with the 3-month average coming to 2.07 million.
Analysts gave the Zentalis Pharmaceuticals Inc (ZNTL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.89. If we narrow down to specifics, the data shows that 0 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 5 recommended ZNTL as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Zentalis Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.8.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information
Instantly ZNTL was in red as seen at the end of in last trading. With action -4.00%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -77.82%, with the 5-day performance at -4.00% in the red. However, in the 30-day time frame, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) is 1.20% up. Looking at the short shares, we see there were 4.97 million shares sold at short interest cover period of 3.27 days.
The consensus price target for the stock as assigned by Wall Street analysts is 10, meaning bulls need an upside of 66.4% from its current market value. According to analyst projections, ZNTL’s forecast low is 4 with 55 as the target high. To hit the forecast high, the stock’s price needs a -1536.9% plunge from its current level, while the stock would need to soar -19.05% for it to hit the projected low.
Zentalis Pharmaceuticals Inc (ZNTL) estimates and forecasts
Data shows that the Zentalis Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -70.63% over the past 6 months, a 44.52% in annual growth rate that is considerably higher than the industry average of 17.60%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at -100.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -50.05%. The 2024 estimates are for Zentalis Pharmaceuticals Inc earnings to increase by 45.10%.
ZNTL Dividends
Zentalis Pharmaceuticals Inc is expected to release its next quarterly earnings report in January.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.83% of Zentalis Pharmaceuticals Inc shares while 98.06% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 101.96%. There are 98.06% institutions holding the Zentalis Pharmaceuticals Inc stock share, with MATRIX CAPITAL MANAGEMENT COMPANY, LP the top institutional holder. As of 2024-06-30, the company held 19.6902% of the shares, roughly 13.96 million ZNTL shares worth $57.1 million.
FMR LLC holds the second largest percentage of outstanding shares, with 12.2383% or 8.68 million shares worth $35.49 million as of 2024-06-30.
